(Q35294697)

7 August 2017

1 reference

title

Pharmacotherapy for schizophrenia and co-occurring substance use disorders. (English)

1 reference

7 August 2017

0 references

0 references

Douglas L Noordsy

1

1 reference

7 August 2017

Alan I Green

series ordinal

2

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 October 2003

1 reference

Current Psychiatry Reports

7 August 2017

published in

1 reference

7 August 2017

volume

5

1 reference

7 August 2017

issue

5

1 reference

7 August 2017

page(s)

340-346

1 reference

https://scigraph.springernature.com/pub.10.1007/s11920-003-0066-5

7 August 2017

exact match

0 references

cites work

Psychotogenic drug use and neuroleptic response

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11920-003-0066-5

Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11920-003-0066-5

Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11920-003-0066-5

Determinants of risk behavior for human immunodeficiency virus/acquired immunodeficiency syndrome in people with severe mental illness

21 January 2018

1 reference

12 December 2020

Use of pharmacy data to assess quality of pharmacotherapy for schizophrenia in a national health care system: individual and facility predictors.

1 reference

12 December 2020

Clinical use of quetiapine in disease states other than schizophrenia.

1 reference

12 December 2020

Decreased substance use in chronically psychotic patients treated with clozapine

1 reference

12 December 2020

A neurobiological basis for substance abuse comorbidity in schizophrenia

1 reference

12 December 2020

Olanzapine treatment for patients with schizophrenia and substance abuse

1 reference

12 December 2020

Olanzapine treatment for patients with schizophrenia and cocaine abuse

1 reference

12 December 2020

Social functioning, psychopathology, and medication side effects in relation to substance use and abuse in schizophrenia

1 reference

12 December 2020

Motivational responses to natural and drug rewards in rats with neonatal ventral hippocampal lesions: an animal model of dual diagnosis schizophrenia

1 reference

12 December 2020

Significant interaction between clozapine and cocaine in cocaine addicts

1 reference

12 December 2020

Medication adherence of individuals with a first episode of psychosis

1 reference

12 December 2020

Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study

1 reference

12 December 2020

A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia

1 reference

12 December 2020

Suicidality in schizophrenia: a review of the evidence for risk factors and treatment options

1 reference

12 December 2020

Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders

1 reference

12 December 2020

Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine?

1 reference

12 December 2020

Detection and management of comorbidity in patients with schizophrenia

1 reference

12 December 2020

Haloperidol increases smoking in patients with schizophrenia

1 reference

12 December 2020

Naltrexone augmentation of neuroleptics in schizophrenia

1 reference

12 December 2020

Psychosis during and after disulfiram use

1 reference

12 December 2020

Heroin and schizophrenia: subjective responses to abused drugs in dually diagnosed patients

1 reference

12 December 2020

Olanzapine for cocaine craving and relapse prevention in 2 patients.

1 reference

12 December 2020

Mortality in current and former users of clozapine.

1 reference

12 December 2020

Disulfiram treatment for alcoholism in severe mental illness

1 reference

12 December 2020

Risperidone pre-treatment reduces the euphoric effects of experimentally administered cocaine.

1 reference

12 December 2020

Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.

1 reference

12 December 2020

A placebo controlled trial of bupropion for smoking cessation in schizophrenia

1 reference

12 December 2020

Recovery-oriented psychopharmacology: redefining the goals of antipsychotic treatment

1 reference

12 December 2020

Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients

1 reference

12 December 2020

Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey

1 reference

12 December 2020

Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse.

1 reference

12 December 2020

Treatment of schizophrenia and comorbid substance use disorder

1 reference

12 December 2020

Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone

1 reference

12 December 2020

Clozapine and substance abuse in patients with schizophrenia

1 reference

12 December 2020

Effects of sustained-release bupropion and supportive group therapy on cigarette consumption in patients with schizophrenia

1 reference

12 December 2020

The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia

1 reference

12 December 2020

Is Substance Abuse in Schizophrenia Related to Impulsivity, Sensation Seeking, or Anhedonia?

1 reference

12 December 2020

Implementing dual diagnosis services for clients with severe mental illness

1 reference

12 December 2020

Relationship of positive and negative symptoms to cocaine abuse in schizophrenia.

1 reference

12 December 2020

Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).

1 reference

12 December 2020

Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence

1 reference

12 December 2020

Use of naltrexone in the treatment of alcohol use disorders in patients with concomitant major mental illness

1 reference

12 December 2020

Substance misuse, psychiatric disorder and violent and disturbed behaviour

1 reference

12 December 2020

Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature

1 reference

12 December 2020

Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia

1 reference

12 December 2020

Six-month outcomes for patients who switched to olanzapine treatment

1 reference

12 December 2020

Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizophrenia: role of 5-HT2 receptor and alpha 1-adrenoceptor antagonism [corrected]

1 reference

12 December 2020

10.1007/S11920-003-0066-5

Identifiers

DOI

1 reference

7 August 2017

1 reference